BD2-Selective Bromodomain Inhibitors for Epigenetic Therapy

The patent applies local quality by designing compounds with specific structural features (substituents at positions 1 and 3 of the pyridine ring, specific amide groups) that confer selective binding affinity for BD2 domain. The molecular structure is optimized locally at specific positions to interact with BD2's acetylated lysine recognition groove, achieving selective inhibition without affecting other bromodomain family members.

The patent employs parameter changes by systematically varying chemical parameters of the pyridine core structure (substituents R1-R6, amide groups, saturation levels) to optimize BD2 binding affinity and selectivity. By adjusting these molecular parameters, the compounds achieve enhanced therapeutic effectiveness while maintaining selective targeting of BD2 domain.

The patent applies segmentation by dividing the BET family of bromodomain proteins into distinct targetable units, specifically focusing on BD2 domain of each BET protein (BRD2, BRD3, BRD4, BRDT). The compound design targets BD2 as a discrete functional unit, enabling selective inhibition that can be applied across multiple disease contexts without requiring separate approaches for each disease type.

The patent implements universality by creating a single compound class (2-oxo-1,2-dihydropyridine-3,5-dicarboxamide derivatives) that can selectively inhibit BD2 domain across multiple BET family proteins and apply to various diseases (autoimmune conditions, viral infections, cancer). This universal BD2-selective inhibitor platform provides broad therapeutic applicability without requiring disease-specific molecular designs.